Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
These effects were also accompanied by increased survival rates in treated subjects.On Tuesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
貝萊德週二透露，Telomir製藥公司（納斯達克股票代碼：TELO）公佈了一項臨床前研究結果，證實其授權分子Telomir-1在扭轉2型糖尿病的數個關鍵參數上的功效。
The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improved oral glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels.
該研究顯示，空腹血糖水平顯著降低至基線水平，口服葡萄糖穩態改善，胰島素抵抗降至接近糖尿病前的水平。
These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance values, a standard measure used to assess insulin sensitivity and resistance.
這些發現得到了家ostasis Model Assessment of Insulin Resistance的顯著改善，這是用於評估胰島素敏感性和耐受性的標準指標。
These effects were also accompanied by increased survival rates in treated subjects.
這些效果還伴隨着接受治療對象的提高存活率。
The company adds that Telomir-1 directly addresses oxidative stress and beta-cell damage by normalizing iron metabolism.
公司補充說，Telomir-1直接解決氧化應激和β-細胞損傷，通過規範鐵代謝來實現。
In collaboration with the India-based research organization Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three doses, in zebrafish models.
與總部位於印度的研究機構Pentagrit合作，Telomir在斑馬魚模型中評估了兩種形式的Telomir-1，口服三種劑量。
Recently, Telomir Pharmaceuticals' preclinical results showed that Telomir-1 demonstrates significant age-reversal effects. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline.
最近，Telomir製藥公司的臨床前結果顯示，Telomir-1展示出重大的年齡逆轉效果。這些效果包括延長健康壽命、改善機動能力以及可量化逆轉與年齡相關的衰退。
Telomir is advancing additional research, including:
Telomir正在推進額外的研究，包括：
- Progeria (causes rapid aging): Evaluating Telomir-1's effects on human progeria cell lines and progeria nematode models to investigate its impact on accelerated aging and telomere function and stability.
- Diabetic Mouse Models: Further validating Telomir-1's efficacy in a mammalian model of Type 2 diabetes.
- Alzheimer's Disease: Initiating studies to assess Telomir-1's potential in mitigating cognitive decline and neurodegeneration.
- Osteoarthritis and Inflammatory Diseases: Evaluating Telomir-1's role in managing joint health and other age-related inflammatory conditions.
- Cancer Models: Exploring Telomir-1's application in combating age-related oncological conditions.
- Progeria（導致快速老化）：評估Telomir-1對人類快老細胞系和快老線蟲模型的影響，以探究其對加速衰老、端粒功能和穩定性的影響。
- 糖尿病小鼠模型：進一步驗證Telomir-1在2型糖尿病哺乳動物模型中的有效性。
- 阿爾茨海默病：啓動研究以評估Telomir-1在減輕認知衰退和神經退行方面的潛力。
- 骨關節炎和炎症性疾病：評估Telomir-1在管理關節健康和其他與年齡相關的炎症性狀況中的作用。
- 癌症模型：探索Telomir-1在對抗與年齡相關的腫瘤條件中的應用。
Price Action: TELO stock is up 15.4% at $4.905 at last check Tuesday.
價格走勢：TELO股票在上週二最新數據顯示漲幅爲15.4%，報4.905美元。
- BlackRock Makes $12 Billion Power Move – Agrees To Acquire HPS To Bolster Private Credit Offerings
- 貝萊德（BlackRock）120億美元重磅動作 - 同意收購HPS以增強私人信貸業務。
Image via Shutterstock.
圖片由shutterstock提供。
